Key result
Intravenous injection of 0.6 mg/kg cilostazol nanoparticles ameliorated neurological deficits and ischemic stroke in MCAO/reperfusion mice without affecting blood pressure or blood flow.
Why the study?
Does intravenous cilostazol nanoparticle dispersion improve neurological deficits and ischemic stroke in a mouse model of cerebral ischemia/reperfusion injury?
Population
Cerebral ischemia/reperfusion-induced injury model (MCAO/reperfusion mice) and rabbit red blood cells
Comparison
Intravenous injection of 0.6 mg/kg cilostazol… vs Cilostazol solutions prepared with…
Design
Preclinical
Authors
Loading...
Nanoparticle cilostazol may aid microvascular protection post-reperfusion; leaves open translation to human stroke trials.
Does intravenous cilostazol nanoparticle dispersion improve neurological deficits and ischemic stroke in a mouse model of cerebral ischemia/reperfusion injury?
Intravenous cilostazol nanoparticles may provide a novel, effective, and safe therapeutic approach for acute ischemic stroke by ameliorating neurological deficits without hemodynamic side effects in a preclinical model.
Nagai et al. (2015) studied Acute Ischemic Stroke. Cilostazol (CLZ) nanoparticles was evaluated on Neurological deficits and ischemic stroke. Intravenous injection of 0.6 mg/kg cilostazol nanoparticles ameliorated neurological deficits and ischemic stroke in MCAO/reperfusion mice without affecting blood pressure or blood flow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: